A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients

Tildrakizumab is a humanized IgG1κ monoclonal antibody that selectively targets the p19 subunit of interleukin IL-23, thereby inhibiting the IL-23/IL-17 axis, which is primarily implicated in the immunopathogenesis of psoriasis. Tildrakizumab is approved for the treatment of moderate-to-severe plaqu...

Descripción completa

Detalles Bibliográficos
Autores principales: Campione, Elena, Lambiase, Sara, Gaeta Shumak, Ruslana, Galluzzo, Marco, Lanna, Caterina, Costanza, Gaetana, Borselli, Cristiana, Artosi, Fabio, Cosio, Terenzio, Tofani, Lorenzo, Dattola, Annunziata, Di Daniele, Francesca, Bianchi, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141711/
https://www.ncbi.nlm.nih.gov/pubmed/37111283
http://dx.doi.org/10.3390/ph16040526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141711/
https://www.ncbi.nlm.nih.gov/pubmed/37111283
http://dx.doi.org/10.3390/ph16040526

Ejemplares similares